ADIPOQ and COVID-19: Obesity driven chronic inflammation, aberrant cytokine activation, decreased adiponectin and increased leptin secretions, and dysfunction of innate and adaptive immunity may contribute to worse clinical outcomes in patients with COVID-19 (50–52).